Base de dados : MEDLINE
Pesquisa : C04.557.470.590 [Categoria DeCS]
Referências encontradas : 700 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 70 ir para página                         

  1 / 700 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381973
[Au] Autor:Zhang F; Yu X; Zeng J; Dai M
[Ad] Endereço:Department of Orthopedics, The First Affiliated Hospital of Nanchang University, Artificial Joints Engineering and Technology Research Center of Jiangxi Province, Nanchang, Jiangxi, China.
[Ti] Título:Mucinous tumor arising in a giant sacrococcygeal teratoma: A rare case report.
[So] Source:Medicine (Baltimore);96(47):e8759, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Teratomas, which most frequently affect adult females, are the most common type of germ cell tumor, it always comprises derivatives of at least 2 germ layers. The most common site of primary teratomas is the ovary. Sacrococcygeal teratomas (SCTs), which are exceedingly rare in adults, are generally found in newborns or children. PATIENT CONCERNS: A 39-year-old woman presented to our clinic with a 1-year history of gradually aggravated difficulty in micturition and defecation, and a tumor in her right buttock present since birth. Appropriate preoperative examinations showed a large (15.6 cm × 12.2 cm × 30.0 cm) multicystic SCT. DIAGNOSES: Histologic examination confirmed a mucinous tumor arising in a giant SCT. INTERVENTIONS: Abdominoperineal rectal resection was performed. OUTCOMES: The patient recovered well and was discharged on day 33 of admission. LESSONS: We report the first case of a mucinous tumor arising in an SCT, in which the teratoma presented mature tissue elements derived only from the endodermal germ layer (keratinous debris).
[Mh] Termos MeSH primário: Neoplasias Císticas, Mucinosas e Serosas/patologia
Neoplasias Primárias Múltiplas/patologia
Neoplasias Pélvicas/patologia
Teratoma/patologia
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Neoplasias Císticas, Mucinosas e Serosas/cirurgia
Neoplasias Primárias Múltiplas/cirurgia
Neoplasias Pélvicas/cirurgia
Região Sacrococcígea/patologia
Região Sacrococcígea/cirurgia
Teratoma/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008759


  2 / 700 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29369188
[Au] Autor:Carlson JW; Rådestad AF; Söderberg-Naucler C; Rahbar A
[Ad] Endereço:Department of Pathology and Cytology, Institute for Oncology-Pathology.
[Ti] Título:Human cytomegalovirus in high grade serous ovarian cancer possible implications for patients survival.
[So] Source:Medicine (Baltimore);97(4):e9685, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Patients diagnosed with high grade serous ovarian adenocarcinoma have a poor prognosis. Recently human cytomegalovirus (HCMV) has been detected in several tumors. Here, we evaluated HCMV in ovarian cancer tissue specimens obtained at pre- and postchemotherapy tumor resection.Available paraffin embedded ovarian cancer tissues from matched pre- and postchemotherapy tumor resection specimens (i.e., diagnostic excisional biopsy prechemotherapy; DEBPC) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT + IDS) from 10 patients with stage IIIC-IV high grade serous ovarian carcinoma (HGS) diagnosed between years 2007 and 2008 at Karolinska University Hospital were examined for HCMV immediate-early protein (HCMV-IE), tegument protein pp65, and nucleic acid (ß2.7) by immunohistochemistry and in situ hybridization.HCMV-IE and pp65 were detected in 8/10 (80%), 4/9 (44%) and in 4/10 (40%), 5/8 in ovarian cancer tissue specimens from DEBPC and NACT + IDS, respectively. HCMV-ß2.7 was detected in all available tissue sections obtained from DEBPC and NACT + IDS. Patients with HCMV-IE or pp65 positive cells in their ovarian tumors at IDS after NACT had a median overall survival of 23.4 and 18.2 months, respectively, compared to 29.6 and 54 months, respectively, in those who did not express HCMV proteins in their tumors.In conclusion, HCMV proteins and nucleic acids are frequently detected at different levels in HGS ovarian carcinoma. Despite the limitation of our study, shorter median overall survival of patients with HCMV-IE and pp65 in their tumor highlights the need to further investigate the role of HCMV in ovarian cancer patients.
[Mh] Termos MeSH primário: Infecções por Citomegalovirus/complicações
Citomegalovirus
Neoplasias Císticas, Mucinosas e Serosas/mortalidade
Neoplasias Ovarianas/mortalidade
[Mh] Termos MeSH secundário: Idoso
Infecções por Citomegalovirus/virologia
Procedimentos Cirúrgicos de Citorredução
Feminino
Seres Humanos
Meia-Idade
Neoplasias Císticas, Mucinosas e Serosas/cirurgia
Neoplasias Císticas, Mucinosas e Serosas/virologia
Neoplasias Ovarianas/cirurgia
Neoplasias Ovarianas/virologia
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009685


  3 / 700 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771168
[Au] Autor:Chan JK; Java JJ; Fuh K; Monk BJ; Kapp DS; Herzog T; Bell J; Young R
[Ad] Endereço:Division of Gynecologic Oncology, California Pacific-Palo Alto Medical Foundation Sutter Research Institute, 3838 California Street #410, San Francisco, CA 94115, United States. Electronic address: chanjohn@sutterhealth.org.
[Ti] Título:The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
[So] Source:Gynecol Oncol;143(3):490-495, 2016 Dec.
[Is] ISSN:1095-6859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To determine the association between timing of adjuvant therapy initiation and survival of early stage ovarian cancer patients. METHODS: Data were obtained from women who underwent primary surgical staging followed by adjuvant therapy from two Gynecologic Oncology Group trials (protocols # 95 and 157). Kaplan-Meier estimates and Cox proportional hazards model adjusted for covariates were used for analyses. RESULTS: Of 497 stage I-II epithelial ovarian cancer patients, the median time between surgery and initiation of adjuvant therapy was 23days (25th-75th%: 12-33days). The time interval from surgery to initiation of adjuvant therapy was categorized into three groups: <2weeks, 2-4weeks, and >4weeks. The corresponding 5-year recurrence-free survival rates were 72.8%, 73.9%, and 79.5% (p=0.62). The 5-year overall survival rates were 79.4%, 81.9%, and 82.8%, respectively (p=0.51; p=0.33 - global test). As compared to <2weeks, the hazard ratio for recurrence-free survival was 0.90 (95%CI=0.59-1.37) for 2-4weeks and 0.72 (95%CI=0.46-1.13) for >4weeks. Age, stage, grade, and cytology were important prognostic factors. CONCLUSIONS: Timing of adjuvant therapy initiation was not associated with survival in early stage epithelial ovarian cancer patients.
[Mh] Termos MeSH primário: Adenocarcinoma de Células Claras/tratamento farmacológico
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Carcinoma Endometrioide/tratamento farmacológico
Quimioterapia Adjuvante/métodos
Procedimentos Cirúrgicos de Citorredução/métodos
Neoplasias Císticas, Mucinosas e Serosas/tratamento farmacológico
Neoplasias Epiteliais e Glandulares/tratamento farmacológico
Neoplasias Ovarianas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adenocarcinoma de Células Claras/patologia
Carboplatina/administração & dosagem
Carcinoma Endometrioide/patologia
Cisplatino/administração & dosagem
Ciclofosfamida/administração & dosagem
Feminino
Seres Humanos
Infusões Intravenosas
Infusões Parenterais
Estimativa de Kaplan-Meier
Meia-Idade
Análise Multivariada
Estadiamento de Neoplasias
Neoplasias Císticas, Mucinosas e Serosas/patologia
Neoplasias Epiteliais e Glandulares/patologia
Neoplasias Ovarianas/patologia
Paclitaxel/administração & dosagem
Prognóstico
Modelos de Riscos Proporcionais
Taxa de Sobrevida
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
8N3DW7272P (Cyclophosphamide); BG3F62OND5 (Carboplatin); P88XT4IS4D (Paclitaxel); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171214
[Lr] Data última revisão:
171214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  4 / 700 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29187496
[Au] Autor:Shibata H; Ohike N; Norose T; Isobe T; Suzuki R; Imai H; Shiokawa A; Aoki T; Murakami M; Mizukami H; Tanaka JI; Takimoto M
[Ad] Endereço:Department of Pathology, Showa University Hospital, Tokyo, Japan hshibata@med.showa-u.ac.jp.
[Ti] Título:Mucinous Cystic Neoplasms Lined by Abundant Mucinous Epithelium Frequently Involve KRAS Mutations and Malignant Progression.
[So] Source:Anticancer Res;37(12):7063-7068, 2017 12.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pancreatic and hepatic mucinous cyst neoplasms (MCNs) have a malignant potential, but indolent MCNs are not uncommon. MATERIALS AND METHODS: The pathological and genetic characteristics of resected MCNs (n=15) categorized by the amount of mucin of the lining epithelium were investigated. RESULTS: MCNs were divided into two groups: (i) a rich (r)-MCN group (n=6), in which more than half of the epithelium was lined by abundant mucinous epithelium; and (ii) a poor (p)-MCN group (n=9), which consisted of the remaining cases. Three patients in the r-MCN group showed invasive carcinoma or high-grade dysplasia, whereas all patients in the p-MCN group showed low-grade dysplasia. Mutations of Kirsten rat sarcoma viral oncogene homolog (KRAS) were more frequent in the r-MCN group (83%) (p-MCN; 11%, p<0.05). CONCLUSION: Mucinous MCNs more frequently have KRAS mutations and higher risk of malignant progression.
[Mh] Termos MeSH primário: Epitélio/metabolismo
Neoplasias Hepáticas/genética
Mutação
Neoplasias Císticas, Mucinosas e Serosas/genética
Neoplasias Pancreáticas/genética
Proteínas Proto-Oncogênicas p21(ras)/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Progressão da Doença
Epitélio/patologia
Feminino
Seres Humanos
Neoplasias Hepáticas/metabolismo
Neoplasias Hepáticas/patologia
Masculino
Meia-Idade
Mucinas/metabolismo
Neoplasias Císticas, Mucinosas e Serosas/metabolismo
Neoplasias Císticas, Mucinosas e Serosas/patologia
Neoplasias Pancreáticas/metabolismo
Neoplasias Pancreáticas/patologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (KRAS protein, human); 0 (Mucins); EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE


  5 / 700 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29187489
[Au] Autor:Zhou W; Saam T; Zhou Y; Trevino J; Liu X; Cao D; Lai J
[Ad] Endereço:Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, P.R. China.
[Ti] Título:Pancreatic Mucinous Cystic Neoplasm Communicating with Main Pancreatic Duct: An Unrecognized Presentation of Pancreatic Mucinous Neoplasm?
[So] Source:Anticancer Res;37(12):7017-7021, 2017 12.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:Mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs) are two well recognized entities of precursor cystic lesions of pancreatic duct adenocarcinoma. The characteristic features of MCNs are the lined mucinous epithelium with underlying ovarian-type stroma, but without communication with the ducts, while that for IPMNs are the communication with the ducts but without the underlying ovarian-type stroma. Here we report a case of MCN communicating with the main pancreatic duct in a 68-year-old woman. The initial radiographic diagnosis was pancreatic IPMN with main pancreatic involvement and this was also confirmed during gross examination. Histologically, the pancreatic cystic neoplasm was lined with mucinous epithelium with underlying ovarian-type of stroma. Immunohistochemical stains confirmed that the stroma cells were positive for ER, PR, alpha-inhibin and focally positive for CD10. The final pathologic diagnosis was pancreatic mucinous cystic neoplasm communicating with the main pancreatic duct. To the best of our knowledge, this is the second pathology confirmed case of MCN communicating with the main pancreatic duct. A careful gross examination and bivalvation of the main duct communicating with the cystic neoplasm helps render the correct diagnosis. If more cases are reported in the future, the MCN communicating with duct could become a new entity of pancreatic mucinous neoplasm.
[Mh] Termos MeSH primário: Adenocarcinoma Mucinoso/diagnóstico
Neoplasias Císticas, Mucinosas e Serosas/diagnóstico
Ductos Pancreáticos/patologia
Neoplasias Pancreáticas/diagnóstico
[Mh] Termos MeSH secundário: Idoso
Carcinoma Papilar/diagnóstico
Diagnóstico Diferencial
Feminino
Seres Humanos
Imuno-Histoquímica
Inibinas/análise
Pâncreas/metabolismo
Pâncreas/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (inhibin-alpha subunit); 57285-09-3 (Inhibins)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE


  6 / 700 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28982877
[Au] Autor:Gungorduk K; Asicioglu O; Braicu EI; Almuheimid J; Gokulu SG; Cetinkaya N; Gungor T; Pakay G; Telli EU; Cuylan ZF; Toptas T; Bilgi A; Ozyurt R; Agacayak E; Ozdemir A; Yildirim N; Taskin S; Oge T; Erol O; Akman L; Turan A; Icen MS; Senol T; Ovali OI; Yucesoy B; Gungorduk O; Temizkan O; Sanci M; Simsek T; Meydanli MM; Harma M; Yasar L; Uysal AD; Karateke A; Ortac F; Ozalp SS; Sehouli J; Muallem MZ
[Ad] Endereço:Department of Gynecology and Gynecologic Oncology, Mugla Education and Research Hospital, Mugla, Turkey.
[Ti] Título:The Impact of Surgical Staging on the Prognosis of Mucinous Borderline Tumors of the Ovaries: A Multicenter Study.
[So] Source:Anticancer Res;37(10):5609-5616, 2017 10.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: The purpose of this study was to prove the effect of complete surgical staging of patients with mucinous borderline ovarian tumors (mBOTs) especially appendectomy on progression-free survival (PFS) and overall survival (OS). PATIENTS AND METHODS: The database of 14 gynecological oncology departments from Turkey and Germany were comprehensively searched for women who underwent primary surgery for an ovarian tumor between January 1, 1998, and December 31, 2015, and whose final diagnosis was mBOT. RESULTS: A total of 364 patients with mBOT with a median age of 43.1 years were included in this analysis. The median OS of all patients was 53.1 months. The majority of cases had Stage IA (78.6%). In univariate and multivariate analyses, radical surgery, omentectomy, appendectomy, lymphadenectomy, and adding adjuvant chemotherapy were not independent prognostic factors for PFS and OS. Furthermore, FIGO stage (≥IC vs.
[Mh] Termos MeSH primário: Procedimentos Cirúrgicos em Ginecologia
Estadiamento de Neoplasias/métodos
Neoplasias Císticas, Mucinosas e Serosas/patologia
Neoplasias Císticas, Mucinosas e Serosas/cirurgia
Neoplasias Ovarianas/patologia
Neoplasias Ovarianas/cirurgia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Apendicectomia
Quimioterapia Adjuvante
Progressão da Doença
Intervalo Livre de Doença
Feminino
Alemanha
Procedimentos Cirúrgicos em Ginecologia/efeitos adversos
Procedimentos Cirúrgicos em Ginecologia/mortalidade
Seres Humanos
Estimativa de Kaplan-Meier
Excisão de Linfonodo
Meia-Idade
Análise Multivariada
Neoplasias Císticas, Mucinosas e Serosas/mortalidade
Neoplasias Ovarianas/mortalidade
Valor Preditivo dos Testes
Modelos de Riscos Proporcionais
Estudos Retrospectivos
Fatores de Risco
Fatores de Tempo
Resultado do Tratamento
Turquia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  7 / 700 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28805821
[Au] Autor:Janouskova H; El Tekle G; Bellini E; Udeshi ND; Rinaldi A; Ulbricht A; Bernasocchi T; Civenni G; Losa M; Svinkina T; Bielski CM; Kryukov GV; Cascione L; Napoli S; Enchev RI; Mutch DG; Carney ME; Berchuck A; Winterhoff BJN; Broaddus RR; Schraml P; Moch H; Bertoni F; Catapano CV; Peter M; Carr SA; Garraway LA; Wild PJ; Theurillat JP
[Ad] Endereço:Institute of Oncology Research, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
[Ti] Título:Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
[So] Source:Nat Med;23(9):1046-1054, 2017 Sep.
[Is] ISSN:1546-170X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:It is generally assumed that recurrent mutations within a given cancer driver gene elicit similar drug responses. Cancer genome studies have identified recurrent but divergent missense mutations affecting the substrate-recognition domain of the ubiquitin ligase adaptor SPOP in endometrial and prostate cancers. The therapeutic implications of these mutations remain incompletely understood. Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-associated SPOP mutants. The resulting reduction of BET protein levels sensitized cancer cells to BET inhibitors. Conversely, prostate cancer-specific SPOP mutations resulted in impaired degradation of BETs, promoting their resistance to pharmacologic inhibition. These results uncover an oncogenomics paradox, whereby mutations mapping to the same domain evoke opposing drug susceptibilities. Specifically, we provide a molecular rationale for the use of BET inhibitors to treat patients with endometrial but not prostate cancer who harbor SPOP mutations.
[Mh] Termos MeSH primário: Adenocarcinoma de Células Claras/genética
Carcinoma Endometrioide/genética
Carcinossarcoma/genética
Neoplasias do Endométrio/genética
Neoplasias Císticas, Mucinosas e Serosas/genética
Proteínas Nucleares/genética
Proteínas Nucleares/metabolismo
Neoplasias da Próstata/genética
Proteínas Serina-Treonina Quinases/metabolismo
Proteínas de Ligação a RNA/metabolismo
Proteínas Repressoras/genética
Fatores de Transcrição/metabolismo
[Mh] Termos MeSH secundário: Acetanilidas/farmacologia
Adenocarcinoma de Células Claras/metabolismo
Animais
Apoptose/efeitos dos fármacos
Azepinas/farmacologia
Carcinoma Endometrioide/metabolismo
Carcinossarcoma/metabolismo
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Cromatografia Líquida
Proteínas Culina/metabolismo
Resistência a Medicamentos Antineoplásicos
Neoplasias do Endométrio/metabolismo
Epigênese Genética
Feminino
Compostos Heterocíclicos com 3 Anéis/farmacologia
Seres Humanos
Immunoblotting
Imuno-Histoquímica
Imunoprecipitação
Masculino
Espectrometria de Massas
Camundongos Nus
Terapia de Alvo Molecular
Mutação
Transplante de Neoplasias
Neoplasias Císticas, Mucinosas e Serosas/metabolismo
Proteínas Nucleares/antagonistas & inibidores
Neoplasias da Próstata/metabolismo
Proteínas Serina-Treonina Quinases/antagonistas & inibidores
Proteínas de Ligação a RNA/antagonistas & inibidores
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Fatores de Transcrição/antagonistas & inibidores
Triazóis/farmacologia
Ubiquitinação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 ((+)-JQ1 compound); 0 (Acetanilides); 0 (Azepines); 0 (BRD3 protein, human); 0 (BRD4 protein, human); 0 (CUL3 protein, human); 0 (Cullin Proteins); 0 (Heterocyclic Compounds, 3-Ring); 0 (Nuclear Proteins); 0 (OTX015); 0 (RNA-Binding Proteins); 0 (Repressor Proteins); 0 (SPOP protein, human); 0 (Transcription Factors); 0 (Triazoles); EC 2.7.1.- (BRD2 protein, human); EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170815
[St] Status:MEDLINE
[do] DOI:10.1038/nm.4372


  8 / 700 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28687431
[Au] Autor:Duconseil P; Périnel J; Autret A; Adham M; Sauvanet A; Chiche L; Mabrut JY; Tuech JJ; Mariette C; Régenet N; Fabre JM; Bachellier P; Delpéro JR; Paye F; Turrini O
[Ad] Endereço:Department of Surgery, Hôpital Nord, Marseille, France. Electronic address: pauline.duconseil@gmail.com.
[Ti] Título:Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC).
[So] Source:Eur J Surg Oncol;43(9):1704-1710, 2017 Sep.
[Is] ISSN:1532-2157
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To compare survival and impact of adjuvant chemotherapy in patients who underwent pancreaticoduodenectomy (PD) for invasive intraductal papillary mucinous neoplasm (IIPMN) and sporadic pancreatic ductal adenocarcinoma (PDAC). METHODS: From 2005 to 2012, 240 patients underwent pancreatectomy for IIPMN and 1327 for PDAC. Exclusion criteria included neoadjuvant treatment, pancreatic resection other than PD, vascular resection, carcinoma in situ, or <11 examined lymph nodes. Thus, 82 IIPMN and 506 PDAC were eligible for the present study. Finally, The IIPMN group was matched 1:2 to compose the PDAC group according to TNM disease stage, perineural invasion, lymph node ratio, and margin status. RESULTS: There was no difference in patient's characteristics, intraoperative parameters, postoperative outcomes, and histologic parameters. Overall survival and disease-free survival times were comparable between the 2 groups. In each group, overall survival time was significantly poorer in patients who did not achieve adjuvant chemotherapy (p = 0.03 for the IIPMN group; p = 0.03 for the PDAC group). In lymph-node negative patients of the IIPMN group, adjuvant chemotherapy did not have any significant impact on overall survival time (OR = 0.57; 95% CI [0.24-1.33]). Considering the whole population (i.e. patients with IIPMN and PDAC; n = 246), patients who did not achieve adjuvant chemotherapy had poorer survival (p < 0.01). CONCLUSIONS: The courses of IIPMN and PDAC were similar after an optimized stage-to-stage comparison. Adjuvant chemotherapy was efficient in both groups. However, in lymph node negative patients, adjuvant chemotherapy seemed not to have a significant impact.
[Mh] Termos MeSH primário: Carcinoma Ductal Pancreático/terapia
Neoplasias Císticas, Mucinosas e Serosas/terapia
Neoplasias Pancreáticas/terapia
[Mh] Termos MeSH secundário: Idoso
Carcinoma Ductal Pancreático/patologia
Carcinoma Ductal Pancreático/secundário
Quimioterapia Adjuvante
Intervalo Livre de Doença
Feminino
França
Seres Humanos
Metástase Linfática
Masculino
Margens de Excisão
Meia-Idade
Invasividade Neoplásica
Estadiamento de Neoplasias
Neoplasia Residual
Neoplasias Císticas, Mucinosas e Serosas/patologia
Neoplasias Císticas, Mucinosas e Serosas/secundário
Neoplasias Pancreáticas/patologia
Pancreaticoduodenectomia
Nervos Periféricos/patologia
Taxa de Sobrevida
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170709
[St] Status:MEDLINE


  9 / 700 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28665051
[Au] Autor:Nishikawa T; Matsumoto K; Tamura K; Yoshida H; Imai Y; Miyasaka A; Onoe T; Yamaguchi S; Shimizu C; Yonemori K; Shimoi T; Yunokawa M; Xiong H; Nuthalapati S; Hashiba H; Kiriyama T; Leahy T; Komarnitsky P; Fujiwara K
[Ad] Endereço:Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
[Ti] Título:Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.
[So] Source:Cancer Sci;108(9):1834-1842, 2017 Sep.
[Is] ISSN:1349-7006
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Veliparib (ABT-888) is a potent, orally bioavailable poly(ADP-ribose) polymerase-1 and -2 inhibitor. This phase 1 study evaluated the tolerability, pharmacokinetic profile, safety, and preliminary antitumor activity of single-agent veliparib in Japanese patients with advanced solid tumors. Eligible patients were assigned to treatment with veliparib at 200 or 400 mg dose; veliparib was self-administered orally twice daily on days 1-28 of 28-day cycles. Dose escalation, following a 3 + 3 design, defined dose-limiting toxicities, the maximum tolerated dose, and the recommended phase 2 dose. Sixteen patients were enrolled (median age, 59 years). Fourteen patients had high-grade serous ovarian cancer, one had primary peritoneal cancer, and one had BRCA-mutated breast cancer. The most frequent treatment-emergent adverse events were nausea and vomiting (93.8% each), decreased appetite (62.5%), abdominal pain, diarrhea, and malaise (31.3% each). A grade ≥3 toxicity was observed in 50% of patients; one patient each in the 200 mg (n = 4) and 400 mg (n = 12) cohorts experienced serious adverse events. Dose-limiting toxicities were observed for one patient at the 400 mg dose. No toxicities leading to death were reported. The recommended phase 2 dose was defined as 400 mg twice daily. The veliparib pharmacokinetic profile was consistent with that reported for the Western population. Two patients, both with ovarian cancer, had a RECIST partial response. Veliparib monotherapy showed manageable tolerability and safety profiles and a predictable pharmacokinetic profile at a 400 mg twice-daily dose, and supports the inclusion of Japanese patients in the multinational phase 3 study (NCT02470585).
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Benzimidazóis/administração & dosagem
Neoplasias Císticas, Mucinosas e Serosas/tratamento farmacológico
Neoplasias Ovarianas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos/toxicidade
Benzimidazóis/toxicidade
Intervalo Livre de Doença
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Dose Máxima Tolerável
Meia-Idade
Neoplasias Císticas, Mucinosas e Serosas/mortalidade
Neoplasias Ovarianas/mortalidade
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Benzimidazoles); 01O4K0631N (veliparib)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170701
[St] Status:MEDLINE
[do] DOI:10.1111/cas.13307


  10 / 700 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28610746
[Au] Autor:Bednar EM; Oakley HD; Sun CC; Burke CC; Munsell MF; Westin SN; Lu KH
[Ad] Endereço:The Department of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, 1155 Herman P. Pressler Dr. Houston, TX 77030, United States.
[Ti] Título:A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
[So] Source:Gynecol Oncol;146(2):399-404, 2017 Aug.
[Is] ISSN:1095-6859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Genetic counseling (GC) and germline genetic testing (GT) for BRCA1 and BRCA2 are considered standard of care for patients with high-grade, non-mucinous epithelial ovarian, fallopian tube, and primary peritoneal cancers (HGOC). We describe a universal genetic testing initiative to increase the rates of recommendation and acceptance of GC and GT to >80% for patients with HGOC at our institution. METHODS: Data from a consecutive cohort of patients seen in our gynecologic oncology clinics between 9/1/2012 and 8/31/2015 for evaluation of HGOC were retrospectively analyzed. Data were abstracted from the tumor registry, medical records, and research databases. Descriptive statistics were used to evaluate patient characteristics and GC, GT, and PARP inhibitor use. Various clinic interventions were developed, influenced by the Plan-Do-Study-Act cycle method, which included physician-coordinated GT, integrated GC, and assisted GC referrals. RESULTS: A cohort of 1636 patients presented to the gynecologic oncology clinics for evaluation of HGOC during our study period, and 1423 (87.0%) were recommended to have GC and GT. Of these, 1214 (85.3%) completed GT and 217 (17.9%) were found to have a BRCA1 or BRCA2 mutation. Among BRCA-positive patients, 167 had recurrent or progressive disease, and 56 of those received PARP inhibitor therapy. CONCLUSIONS: The rates of GC and GT recommendation and completion among patients with HGOC at our institution exceeded 80% following the implementation of a universal genetic testing initiative. Universal genetic testing of patients with HGOC is one strategy to identify those who may benefit from PARP inhibitor therapy.
[Mh] Termos MeSH primário: Adenocarcinoma de Células Claras/genética
Carcinoma Endometrioide/genética
Genes BRCA1
Genes BRCA2
Testes Genéticos
Síndrome Hereditária de Câncer de Mama e Ovário/diagnóstico
Neoplasias Císticas, Mucinosas e Serosas/genética
Neoplasias Epiteliais e Glandulares/genética
Neoplasias Ovarianas/genética
[Mh] Termos MeSH secundário: Adenocarcinoma de Células Claras/tratamento farmacológico
Adenocarcinoma de Células Claras/patologia
Adulto
Idoso
Idoso de 80 Anos ou mais
Carcinoma Endometrioide/tratamento farmacológico
Carcinoma Endometrioide/patologia
Aconselhamento Genético
Síndrome Hereditária de Câncer de Mama e Ovário/genética
Seres Humanos
Programas de Rastreamento
Meia-Idade
Gradação de Tumores
Neoplasias Císticas, Mucinosas e Serosas/tratamento farmacológico
Neoplasias Císticas, Mucinosas e Serosas/patologia
Neoplasias Epiteliais e Glandulares/tratamento farmacológico
Neoplasias Epiteliais e Glandulares/patologia
Neoplasias Ovarianas/tratamento farmacológico
Neoplasias Ovarianas/patologia
Inibidores de Poli(ADP-Ribose) Polimerases/uso terapêutico
Melhoria de Qualidade
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Poly(ADP-ribose) Polymerase Inhibitors)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170615
[St] Status:MEDLINE



página 1 de 70 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde